Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TNXP 
Tonix Pharmaceuticals Holding Corp (TNXP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: TNXP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $67.67
1 Year Target Price $67.67
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.89% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 164.89M USD | Price to earnings Ratio 0.01 | 1Y Target Price 67.67 |
Price to earnings Ratio 0.01 | 1Y Target Price 67.67 | ||
Volume (30-day avg) 2 | Beta 1.88 | 52 Weeks Range 6.76 - 72.00 | Updated Date 10/18/2025 |
52 Weeks Range 6.76 - 72.00 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2537 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1416.22% |
Management Effectiveness
Return on Assets (TTM) -39.97% | Return on Equity (TTM) -77.51% |
Valuation
Trailing PE 0.01 | Forward PE - | Enterprise Value 91853949 | Price to Sales(TTM) 16.77 |
Enterprise Value 91853949 | Price to Sales(TTM) 16.77 | ||
Enterprise Value to Revenue 9.34 | Enterprise Value to EBITDA 0.94 | Shares Outstanding 8765896 | Shares Floating 8761250 |
Shares Outstanding 8765896 | Shares Floating 8761250 | ||
Percent Insiders 0.05 | Percent Institutions 16.11 |
Upturn AI SWOT
Tonix Pharmaceuticals Holding Corp
Company Overview
History and Background
Tonix Pharmaceuticals Holding Corp. was founded in 2007. It is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics to treat and prevent human diseases and lessen human suffering. The company has evolved from focusing primarily on pain management to a broader range of central nervous system (CNS) and infectious diseases.
Core Business Areas
- CNS Disorders: Development of therapies for central nervous system (CNS) conditions, including fibromyalgia, post-traumatic stress disorder (PTSD), and other neurological disorders.
- Infectious Diseases: Development of vaccines and antiviral therapies for infectious diseases such as COVID-19 and smallpox.
- Rare Diseases: Development of therapies for rare diseases.
Leadership and Structure
Dr. Seth Lederman is the Chief Executive Officer and Chairman of the Board. The company operates with a typical structure including executive management, research and development, clinical operations, and finance departments.
Top Products and Market Share
Key Offerings
- TNX-102 SL (Edivirivant): A sublingual formulation of cyclobenzaprine being developed for the management of fibromyalgia. It is currently in Phase 3 clinical trials. Market share data not yet available as it's not yet approved. Competitors include drugs from companies like Eli Lilly (Cymbalta) and Pfizer (Lyrica), although TNX-102 SL has a unique mechanism of action (MOA).
- TNX-1800 (COVID-19 Vaccine): A live virus vaccine based on horsepox virus being developed as a potential COVID-19 vaccine. Market share data not yet available as it's not yet approved. Competitors include Moderna (mRNA), Pfizer/BioNTech (mRNA), and Johnson & Johnson (viral vector).
- TNX-801 (Smallpox Vaccine): A live virus vaccine being developed to protect against smallpox and monkeypox. Market share data not yet available as it's not yet approved. Competitors include Emergent BioSolutions (ACAM2000) and Bavarian Nordic (JYNNEOS).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for CNS disorders and vaccines is substantial and growing, driven by aging populations and increasing awareness of mental health issues and infectious disease threats.
Positioning
Tonix Pharmaceuticals is positioned as a clinical-stage company focused on innovative therapies for unmet medical needs. Its competitive advantage lies in its unique drug candidates and vaccine platforms.
Total Addressable Market (TAM)
The TAM for fibromyalgia, PTSD, and infectious diseases is estimated to be in the billions of dollars. Tonix is targeting niche markets within these larger therapeutic areas.
Upturn SWOT Analysis
Strengths
- Novel drug candidates and vaccine platforms
- Experienced management team
- Focus on unmet medical needs
- Strong intellectual property portfolio
Weaknesses
- Lack of approved products and revenue
- High cash burn rate
- Dependence on clinical trial success
- Significant dilution due to funding
Opportunities
- Successful clinical trial results
- Regulatory approval of its drug candidates
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established pharmaceutical companies
- Patent challenges
- Market access and reimbursement challenges
Competitors and Market Share
Key Competitors
- LLY
- PFE
- JNJ
- EBS
- BAVN
Competitive Landscape
Tonix Pharmaceuticals faces intense competition from established pharmaceutical companies and other biotech companies. Its success depends on differentiating its products and navigating the regulatory landscape.
Growth Trajectory and Initiatives
Historical Growth: The company's growth is dependent on the success of its clinical trials and regulatory approvals. Historically, it has not generated significant revenue.
Future Projections: Future growth is projected based on potential regulatory approvals. Analyst estimates vary widely due to the uncertainty of clinical trials and regulatory processes.
Recent Initiatives: Recent initiatives include advancing clinical trials for TNX-102 SL and TNX-1800, and TNX-801 as well as exploring partnerships and collaborations.
Summary
Tonix Pharmaceuticals is a clinical-stage company with promising drug candidates, but it faces significant risks. Its success hinges on positive clinical trial results and regulatory approvals. The company has a high cash burn rate and is dependent on external funding. The market remains very competitive, and the clinical trials have unpredictable results.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Financial information subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tonix Pharmaceuticals Holding Corp
Exchange NASDAQ | Headquaters Chatham, NJ, United States | ||
IPO Launch date 2012-05-10 | Co-Founder, President, CEO & Chairman Dr. Seth Lederman M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 81 | Website https://www.tonixpharma.com |
Full time employees 81 | Website https://www.tonixpharma.com | ||
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure. Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.